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أنواع العدوى االنتهازية احملددة ملرض العوز املناعي 
الفريوسي املكتسب )اإليدز( يف جمموعة من 77 
مريضا عمانيا مرّقدا مصابا باإليدز
)اأ اأ( باخلري، )ز ك( امُلحّرمي، �صيام جاجنويل، علي اجلابري
امللخ�ص: الهدف: معظم املضاعفات والوفيات الناجتة عن مرض العوز املناعي الفريوسي املكتسب تنتج من العدوى االنتهازية، يف حني أن نسبة مثل هذه 
العدوى يف الدول املتقدمة قد مت نشرها، تظل املعلومات من العامل العريب قليلة فيما خيص تارخيه الطبيعي وأعراضه وشفاء املرضى املرّقدين. متت دراسة 
أنواع ونسبة العدوى االنتهازية بطريقة استعادية يف لفيف من املرضى العمانيني املصابني مبرض العوز املناعي املكتسب املرّقدين يف مستشفى جامعي.
الطريقة: مشلت الدراسة 77 مريضا عمانيا مصابا باملرض، مت ترقيدهم يف مستشفى تعليمي ثالثي يف مسقط، ُعمان، يف الفرتة من يناير 1999 إىل 
ديسمرب 2008. وقد مت التشخيص أثناء الرتقيد األول، حيث مل يتم البدء بالعالج باألدوية املضادة لفريوس العوز املناعي املكتسب. وقد مت حتليل 
العدوى االنتهازية  العدوى االنتهازية. النتائج: كان لدى 45 مريضا )%58( واحدة او أكثر من  السريرية واملخربية لكل نوع من  النتائج  خمتلف 
احملددة ملرض العوز املناعي الفريوسي املكتسب. كان االلتهاب الرئوي الطفيلي األكثر شيوعا )%25(، تاله التهاب السحايا الفطري )اْلِتهاُب السَّحايا 
)داُء  الدماغي  والطفيلي   ،)15%( املنتشر  والسّل   ،)17%( للَخالَيا(  َُضخُِّم 
امل )الَفريوُس  الفريوسي  الشبكية  التهاب  مث   ،)22%( سَتْخِفيات( 
ُ
بامل
ُتـََفطَِّرُة الطَّرْيِيَّة اخللوية، بينما عاىن مريض آخر من داُء اللِّيْشمانِيَّاِت احَلَشِوّي. كان لدى 
َُقوَّسات( )%12.5(. عاىن مريض واحد فقط من بكترييا امل
امل
ُمعظم املرضى )%77( خاليا مناعية )سي دي 4( < 200 خلية/ ميكروليرت. تُويف عشرة مرضى )%22( أثناء ترقديهم، مخسة منهم )%50( نتيجة 
انتشار فريوس تضخم اخلاليا. اخلال�صة: كان هناك طيفا كبريا من أنواع العدوى االنتهازية لدى مرضى العوز املناعي الفريوسي املكتسب املرقدين يف 
سَتْخِفيات(  مها األكثر انتشارا، بينما كان انتشار فريوس تضخم اخلاليا أهم سبب للوفاة. 
ُ
ُعمان. التهاب الطفيل الرئوي والتهاب السحايا الدماغي )بامل
نتمىن أن تكون هذه النتائج وسيلة إىل إثراء معرفة املختصني املعاجلني ملرضى فريوس العوز املناعي املكتسب يف ُعمان ومنطقة اخلليج.
مفتاح الكلمات: فريو�ض العوز املناعي املكت�صب، مر�ض العوز املناعي املكت�صب، العدوى االنتهازية، ُعمان.
abstract: Objectives: Most of the morbidity and mortality in human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) result from opportunistic infections (OIs). Although the spectrum of OIs in HIV 
infected patients from developing countries has been reported, there is a paucity of data on the natural history, 
pattern of disease, and survival of hospitalised patients with HIV/AIDS, particularly in Arab countries. The aim 
of this study was to study retrospectively the spectrum and frequency of various OIs in a cohort of hospitalised 
HIV-infected Omani patients. Methods: Included in the study were 77 HIV-infected Omani patients admitted to a 
tertiary care teaching hospital in Muscat, Oman, between January 1999 and December 2008. They were diagnosed 
on their first admission and hence were not on highly active antiretroviral therapy (HAART) at presentation. The 
frequency of various clinical and laboratory findings and individual OIs were analysed. Results: In total, 45 patients 
(58%) had one or more AIDS-defining OIs. Pneumocystis jiroveci pneumonia (PCP) was commonest (25%), followed 
by cryptococcal meningitis (22%), cytomegalovirus (CMV), retinitis (17%), disseminated tuberculosis (15%), and 
cerebral toxoplasmosis (12.5%). Only one patient with Mycobacterium avium-intracellulare (MAI) was identified 
and one patient had disseminated visceral leishmaniasis. The majority of patients (77%) had CD4+ counts <200 
cells/μL. Ten patients (22%) died during hospital stays, with five deaths (50%) being caused by disseminated CMV 
infection. Conclusion: A wide spectrum of OIs is seen in hospitalised HIV-infected patients in Oman. P. jiroveci 
pneumonia and cryptococcal meningitis were the commonest OIs, while disseminated CMV was the commonest 
cause of death. We hope these results will advance the knowledge of specialists treating HIV in Oman and the Gulf 
region.
Keywords: HIV; AIDS; Opportunistic infections; Oman.
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The emergence and pandemic spread of human immunodeficiency virus/acquired immune deficiency syndrome 
(HIV/AIDS) constitutes the greatest health 
challenge in modern times. According to estimates 
by the World Health Organization and the Joint 
United Nations Programme on HIV/AIDS 
(UNAIDS), 34 million people were living with HIV 
at the end of 2010. That same year, some 2.7 million 
people became newly infected, and 1.8 million died 
of AIDS.1
Infections associated with severe 
immunodeficiency are known as opportunistic 
infections (OIs) because they take advantage 
of a weakened immune system. Some of these 
OIs are used to mark the stages of HIV/AIDS.2 
Before the widespread use of potent combination 
antiretroviral therapy (ART), OIs were the principal 
cause of morbidity and mortality in HIV-infected 
patients worldwide. In one study, the mortality rate 
among individuals with a history of preventable OIs 
was 66.7 per 100 people per year compared with 2.3 
per 100 people per year for those without a history 
of preventable OIs.3
The first case of HIV/AIDS in Oman was 
reported in 1984.4 As of 31st December 2009, 1,119 
Omanis were living with HIV/AIDS with more 
than 50% of them between 15 and 35 years of age. 
Around 100 new cases of HIV/AIDS are diagnosed 
annually in Oman.5 During 2009, 116 new cases 
of HIV infection were reported by the Ministry of 
Health in Oman, which makes it the highest annual 
number reported since 1995.5
Many organisms responsible for OIs in patients 
with HIV/AIDS have similar clinical presentation 
and the type of pathogen responsible for morbidity 
and mortality can vary from region to region. 
The identification of such pathogens in Oman is 
essential for clinicians providing care for these 
patients. Hence, the present retrospective study was 
performed to evaluate the spectrum of various OIs 
and determine their relative frequencies in a cohort 
of hospitalised HIV-infected Omani patients.
Methods
This was a retrospective chart review study. A 
total of 77 Omani patients with HIV/AIDS who 
were admitted to Sultan Qaboos University (SQU) 
Hospital, Muscat, Oman, between January 1999 
and December 2008 were investigated for a variety 
of AIDS-defining OIs at the time of their HIV 
diagnosis. All patients were diagnosed on their 
first admission and hence were not on highly active 
antiretroviral therapy (HAART) at presentation. 
Appropriate clinical samples, including sputum, 
bronchoalveolar lavage (BAL), cerebrospinal fluid 
(CSF), and bone marrow aspirates, as indicated by 
the clinical presentation, were collected. Computed 
tomography (CT) and magnetic resonance imaging 
(MRI) scans of the brain, and high resolution CT 
chest scans were performed as per symptoms 
and clinical presentations. The following criteria 
were used to define an OI concern. In the case of 
cryptococcal meningitis, OI was defined by the 
demonstration of Cryptococcus sp. yeast cells in 
the CSF by India ink staining, antigen presence by 
latex agglutination, or growth of cells in a culture. In 
the case of cerebral toxoplasmosis, OI was defined 
by the demonstration of multiple ring-enhancing 
cerebral parenchymal lesions on contrast-enhanced 
CT or MRI scans in the presence of anti-toxoplasma 
antibody in serum and clinical response to anti-
toxoplasma therapy. In the case of Pneumocystis 
jiroveci pneumonia (PCP), OI was proven through 
bilateral, diffuse, interstitial infiltrates on chest 
radiograph or high-resolution CT, with hypoxaemia 
(PaO2 <12 kPa) and/or demonstration of P. jiroveci 
in induced sputum. In the case of disseminated 
tuberculosis, OI was defined by clinical features 
Advances in Knowledge
- This study provides a scientific account of the epidemiology of AIDS defining opportunistic infections (OIs) and their burden on Omani 
HIV-infected patients. 
Application to Patient Care 
- This study provides guidance for developing local guidelines on prophylaxis and management of these infections.
- The results can be used to guide the HIV/AIDS programme in Oman on future directions in HIV care and how to address the issues 
relating to late diagnoses.
- Recommendations for primary prophylaxis for AIDS-defining OIs can be made on the basis of these findings, which may be different 
from those used in industrialised countries. 
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suggestive of tuberculosis (TB) with concurrent 
involvement of at least two non-contiguous 
organs, in the presence of bacteriological and/or 
histopathological evidence of TB and improvement 
with anti-tuberculosis therapy. Entry and analysis 
of all available data were performed using the 
Statistical Package for the Social Sciences (SPSS), 
Version 16.0, (IBM, Chicago, IL, USA). Entered 
data were double-checked for discrepancies. The 
frequency of various clinical and laboratory findings 
and the frequencies of individual OIs are expressed 
as percentages.
Ethical approval was obtained from the SQU 
Ethics and Research Committee before starting 
this study. Patients’ consent was not required as the 
study was retrospective.
Results 
A total of 77 HIV-positive Omani patients were 
included. Their demographic data is presented 
in Table 1. Of those participating in the study, 
45 patients (58%) (38 ± 12 years, males = 62%) 
presented with one or more AIDS-defining OIs. In 
these patients, 72 episodes of AIDS-defining OIs 
were diagnosed (1.6 OI episodes/patient). During 
the same hospitalisation period, 24 patients (53%) 
presented with two or more AIDS-defining OIs. 
Of the patients who presented with one or more 
OI, 73% were male. As shown in Table 2, PCP was 
the commonest AIDS-defining OI (25%), followed 
by cryptococcal meningitis (22%), invasive CMV 
disease/retinitis (17%), disseminated TB (15%), 
and cerebral toxoplasmosis (12.5%). Only one 
patient suffered infection with Mycobacterium 
avium-intracellulare (MAI). Cryptosporidiosis, 
microsporidiosis, and invasive Candida infections 
presented in 3%, 1.5% and 1.5% of cases, respectively. 
In addition, one patient had disseminated visceral 
leishmaniasis. 
CD4+ cell counts were performed in all 77 
patients. The majority of patients (77%) had CD4+ 
counts of <200 cells/μL at their initial presentation 
to the hospital. The mean CD4+ cell count was 72 
cells/μL in those with AIDS-defining OIs versus 301 
cells/μL in the group not suffering from an AIDS-
defining OI. Figure 1 shows mean CD4+ cell counts 
at the time of diagnosis of each AIDS-defining OI. 
A total of 10 patients with AIDS-defining 
OIs (22%) died during their hospital stays. Five 
deaths (50%) were caused by disseminated CMV 
infections. The remaining 5 deaths were caused 
by cryptococcal meningitis (2 patients), cerebral 
toxoplasmosis (2 patients), and disseminated MAI 
(1 patient). Although PCP was the commonest 
AIDS-defining OI, no death was attributed to this 
infection in our cohort.
Discussion
Before the widespread use of potent combination 
ART, OIs were the principal cause of morbidity 
and mortality in this population. In the early 1990s, 
Table 1: Demographic characteristics of HIV-infected 
patients
Total number of patients 77
Age in years, mean 
(range)
37.5 (13–66)
Male gender, number (%) 48 (62%)
CD4 at diagnosis of HIV 
infection, mean (range)
167 cells/mm3 (1 cell/
mm3–1200 cells/mm3
Viral load at diagnosis 
of HIV infection, mean 
(range)
330,000 RNA copies/ml (60 
RNA copies/ml–5,000,000 
RNA copies/ml)
 RNA = ribonucleic acid; HIV = human immunodeficiency virus
Table 2: AIDS-defining opportunistic infections (OIs) 
and their frequencies
AIDS-defining OI Number of 
OI events








Tuberculosis (disseminated) 11 15











AIDS = acquired immune deficiency syndrome; OI = opportunistic 
infection; PCP = Pneumocystis jiroveci pneumonia; CMV = 
cytomegalovirus; MAI = Mycobacterium avium-intracellulare. 
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the use of chemoprophylaxis and better strategies 
for managing acute OIs contributed to improved 
quality of life and patient survival.6 However, the 
widespread use of ART starting in the mid-1990s 
has had the most profound influence on reducing 
OI-related mortality in HIV-infected persons 
in countries where therapies are accessible and 
affordable.6–8
Combination ART was offered to <10% of 
HIV-infected individuals in Oman in 2004.9 An 
estimated 500 Omani patients received ART in 
2008.10 Despite the availability of ART in Oman, 
OIs continue to cause considerable morbidity 
and mortality for three primary reasons: 1) many 
patients are unaware of their HIV infection and 
seek medical care when an OI becomes the initial 
indicator of their disease; 2) certain patients are 
aware of their HIV infection, but do not take ART, 
and 3) some patients are prescribed ART, but fail 
to attain adequate virologic and immunologic 
response because of factors related to adherence, 
pharmacokinetics, or other unexplained biologic 
factors.11 Thus, although hospitalisation and death 
from OIs have decreased in those countries in 
which ART is accessible and affordable, OIs remain 
a leading cause of morbidity and mortality in HIV-
infected persons.12 Clinicians should be aware of 
the epidemiology of such infections in Oman in 
order to provide comprehensive high-quality care 
for these patients. A wide variety of these infections 
are encountered in the HIV/AIDS population, 
including bacteria, fungi, viruses, and protozoa. 
Very often, these represent not new infections but 
the reactivation of an old infection.
In this study, 58% of people who were diagnosed 
with HIV presented with an AIDS-defining OI and 
more than half of them (53%) had two or more 
OIs. The proportion of persons with a CD4+ cell 
count of <200 cells/μL at the time of HIV infection 
diagnosis was 77%. This finding is consistent with 
data from India where 83.4% of patients were late 
presenters.13 However, data from Europe show 
that only one-third of patients were defined as 
late HIV presenters.14 Both the above findings 
were interesting. Whatever the underlying causes, 
reducing the number of late-stage diagnoses of 
HIV infection through earlier and more widespread 
testing, and promoting early introduction and 
adherence to ART will substantially reduce the 
burden of OIs. As mentioned earlier, 73% of the 
Omani patients who presented with one or more 
OIs were male; this warrants a second mention in 
order to reference the national percentage and its 
association with the epidemiology of HIV infections 
in Oman, where males accounted for 74% of all 
reported HIV/AIDS cases in 2008.10
 
Figure 1: Mean CD4 counts at time of diagnosis of each AIDS-defining OI.
AIDS = acquired immune deficiency syndrome; OI = opportunistic infection; TB = tuberculosis; PCP = Pneumocystis jiroveci pneumonia; CMV 
= cytomegalovirus; MAC/MAI = Mycobacterium avium complex/Mycobacterium avium-intracellulare
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PCP was the commonest AIDS-defining OI, 
accounting for 25% of all diagnosed OI events in 
our study. A total of 18 patients (23%) with HIV/
AIDS had PCP as an AIDS-defining OI at their first 
presentation. The prevalence of PCP in our cohort 
was higher than that reported in Lebanon (10.9%), 
and is very much higher than in Europe where only 
2–3% of PCP cases were reported among HIV/
AIDS patients.15,16 Before the widespread use of 
primary PCP prophylaxis and ART, PCP occurred 
in 70–80% of patients with AIDS.17 All cases in 
this cohort occurred among patients with CD4+ 
counts of <200 cells/µL.17 A definitive diagnosis of 
PCP with a demonstration of organisms in induced 
sputum samples or BAL fluid was made in 11 
patients. A presumptive diagnosis of PCP was made 
in the remaining 7 patients. 
Oral candidiasis was the most common OI (59%) 
and our finding is similar to that reported in Nepal 
by Sharma et al.18 Some investigators from India, 
have reported oral candidiasis as the second most 
common infection in AIDS patients, while others 
have reported very low incidence of candidiasis 
(27.7%).19,20 
Mycobacterium TB was the commonest isolate 
reported in a few studies from Hong Kong21 and 
India.22 Pulmonary TB was observed in 35% and 
extra-pulmonary TB in 21% of Omani cases. This 
is similar to data from Brazil where pulmonary TB 
was the commonest OI (52.9%).23 HIV infection is 
a strong risk factor for active TB in persons with 
latent M. tuberculosis infection. Disseminated TB 
accounts for 15% of all OI events (14% of all HIV 
patients). Disseminated TB, on the other hand, was 
reported in 7.8% of the cohort from Lebanon.15
In 2008, there were an estimated 1.5 million 
new cases of tuberculosis among persons with HIV 
infection, and TB accounted for 26% of AIDS-related 
deaths.24 In the same year, 1.4 million patients with 
TB were tested globally for HIV, and 81 countries 
tested more than half of their patients with TB for 
HIV. Only 4% of all persons infected with HIV were 
screened for TB in the same year.25 TB is endemic 
in some countries like India, and is the commonest 
cause of death in AIDS patients.26 HIV patients are 
at increased risk of developing active TB because of 
the high rate of reactivation of latent infection and 
the high degree of susceptibility to new infection.27 
Cryptosporidium infection was observed 
in only 3% of Omani cases. This is in contrast to 
data from Ethiopia where 21% of HIV patients 
had Cryptosporidium.28 Cryptosporidium parvum 
is an enteric pathogen and a common cause of 
gastroenteritis in humans. In patients with HIV, 
cryptosporidiosis may cause potentially fatal 
complications, including bile duct damage.29 The 
rate of infection among individuals with HIV/
AIDS in many countries has subsided considerably 
because of the use of ART.30
Cryptococcus neoformans is the most important 
cause of invasive fungal disease in patients with 
HIV worldwide. Meningitis is the commonest 
clinical manifestation of invasive cryptococcosis 
in patients with HIV. In our study, Cryptococcus 
meningitis accounted for 22% of OI events (21% of 
all HIV patients). Indian reports show the incidence 
of cryptococcal infection (including meningitis) 
to be only 6–8%, whereas it is about 5–11% in 
the USA, 33% in Africa, and 28.5% in Thailand.31 
Interestingly, none of the patients in the Lebanese 
cohort developed cryptococcal meningitis.15 The 
exact explanation for such high incidence in Oman 
is unclear. As a result, primary prophylaxis for 
invasive cryptococcal disease is widely practised by 
many physicians caring for HIV-infected patients in 
Oman. 
Toxoplasmosis, caused by the protozoon 
Toxoplasma gondii, is one of the major OIs afflicting 
HIV patients. Serological tests play a crucial role 
in the diagnosis of toxoplasmosis in immune-
competent persons.32 The prevalence rate of latent 
toxoplasmosis in HIV/AIDS vary from 3–97% 
based on ethnicity and other factors.33 Cerebral 
toxoplasmosis is the most common cause of focal 
neurological disorders in HIV patients. In our 
cohort, cerebral toxoplasmosis accounted for 12.5% 
of all AIDS-defining OIs (12% of all HIV patients). 
In a study from Lebanon, neurotoxoplasmosis was 
reported in 21.9% of the HIV-infected patients.15 
This striking difference probably reflects differences 
in social behaviour between the two populations. In 
our cohort, all patients with cerebral toxoplasmosis 
had positive IgG for toxoplasmosis, CT/MRI 
evidence of compatible brain lesions, and clinical and 
radiological response to therapy for toxoplasmosis.
Both MAI and leishmaniasis were uncommon 
in our cohort, accounting for only 1.5% of all 
AIDS-associated OIs (1.3% of the cohort). Primary 
prophylaxis for MAI is not routinely practised in 
Oman.
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Conclusion
This study shows clearly the necessity of specific 
measures to prevent OIs. Although many patients 
benefit from ART, not all patients are willing to 
take it. Many patients cannot tolerate or adhere 
to the complex drug regimes that constitute this 
therapy, and immunity may not be restored to a 
level that substantially reduces the risk of OIs in all 
patients. With better knowledge and diagnosis of 
OIs in HIV patients, clinicians and health planners 
can tackle the AIDS epidemic in a more effective 
manner. Specific antimicrobial prophylaxis by 
itself or in combination with ART can reduce the 
substantial morbidity and mortality caused by OIs 
in patients with HIV infections. Early diagnosis of 
OIs and prompt treatment definitely contributes to 
increased life expectancy among infected patients, 
thus delaying the progression to AIDS.
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